Topical cyclosporine in the management of shield ulcers.
Cornea
; 23(2): 194-200, 2004 Mar.
Article
em En
| MEDLINE
| ID: mdl-15075890
ABSTRACT
PURPOSE:
To report our experience with 0.05%-2% topical cyclosporine in the treatment of 4 cases of severe, corticosteroid-resistant, vernal keratoconjunctivitis with shield ulcers.METHODS:
Four patients with shield ulcers not responding to medical treatment with topical steroids, antihistamines, and mast-cell stabilizers were treated with 0.05%-2% topical cyclosporine. The frequency of application was 4 times daily in all cases, and the concentration was adjusted according to the clinical status starting with 2%.RESULTS:
Healing of ulcers with no epithelial defect occurred in 10 days with the 2% concentration in all cases. The patients experienced no side effects except for a burning sensation during administration. Recurrences occurred when the concentration was decreased to 0.05% in 3 cases. The recurrences were effectively treated with 1% concentration in all cases, and patients were stable with this concentration for at least 6 months.CONCLUSIONS:
Topical cyclosporine is an effective treatment alternative in the management of shield ulcers in patients with vernal keratoconjunctivitis. The 1% concentration seems to be the minimal effective concentration in such cases in our experience, but further controlled studies are needed to support our findings.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Úlcera
/
Conjuntivite Alérgica
/
Ciclosporina
/
Imunossupressores
Limite:
Adolescent
/
Child
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2004
Tipo de documento:
Article